Overall, our work demonstrates that the long-acting E. coli asparaginase CalPegA enhances the anti-leukemic effect of the BCL-2 inhibitor S55746, but does not impact the activity of the MCL-1 inhibitor S63845 in AML cell lines, patient-derived primary AML samples, and in AML xenograft mouse models. The gene discussed is MCL1; the disease is acute myeloid leukemia.